Company Filing History:
Years Active: 2004-2008
Title: Guy Warnier: Innovator in Cancer Research
Introduction
Guy Warnier is a notable inventor based in Brussels, Belgium. He has made significant contributions to the field of cancer research, particularly in the area of tumor antigens and cytotoxic T lymphocyte (CTL) clones. With a total of 2 patents, his work is paving the way for advancements in cancer diagnostics and treatment.
Latest Patents
Warnier's latest patents focus on the isolation of CTL clones that are specific for proteins of the MAGE family. The first patent describes a novel procedure for isolating these CTL clones through successive stimulation and testing of lymphocytes with antigen-presenting cells. This innovative approach allows for the identification of CTL clones that recognize antigens derived from various expression systems. The second patent relates to nucleic acid molecules encoding antigenic peptides from MAGE molecules that bind to HLA. One example includes a nucleic acid molecule coding for the peptide GVYDGREHTV, which binds to HLA-A2. These discoveries are crucial for diagnosing and treating various pathological conditions.
Career Highlights
Guy Warnier is affiliated with the Ludwig Institute for Cancer Research Limited, where he continues to advance his research. His work has garnered attention for its potential impact on cancer therapies and immunology.
Collaborations
Warnier collaborates with esteemed colleagues such as Pascal Chaux and Rosalie Luiten, contributing to a dynamic research environment focused on innovative cancer solutions.
Conclusion
Guy Warnier's contributions to cancer research through his patents and collaborations highlight his role as a key innovator in the field. His work continues to inspire advancements in the diagnosis and treatment of cancer.